

COVID 19 Pseudoviral Particles, JN.4 Variant Coronavirus Pseudovirus | COVID-19 pseudovirus

SARS-CoV-2 Pseudoviral Particles, JN.4 Variant

CATALOG #

AAA62265


PRODUCT SYNONYMS

COVID 19 Pseudoviral Particles; JN.4 Variant Coronavirus; SARS-CoV-2 Pseudoviral Particles; JN.4 Variant; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Pseudoviral Particles; COVID-19 pseudovirus

PRODUCT SPECIFICATIONS


Form/Format	5 ml, for one multi-well plates; PP per mL > 1.0E+07
Features	Robust: Excellent signal to noise (basal) ratio Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
Dry Ice Note	The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
Preparation and Storage	Upon receiving it, store at -70 oC right away. Thaw* before immediate use. *Note: read the instruction for thawing in the following protocol carefully. Do not aliquot and refreeze. Shelf Life: Six months from the date of shipping when stored at -70 oC

IMAGES



Application Data

Figure 2. Pseudoviral Particle (PP) Infection Assays (SARS-CoV-2 JN.4 subtype pseudoviral particles on HEK293-ACE2 cells) (Luminescence plate reader: BioTek Synergy 2, gain 255)Legends: (-): MLV control (w/o envelope spike protein) JN.4: SARS-CoV-2 JN.4 variant MLV pseudoviral particles



Application Data

Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein

ADDITIONAL INFORMATION

Related Product Information for COVID-19 pseudovirus	It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as entry receptor and human proteases as entry activators. The virus surface spike protein (S) mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to its human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and is proteolytically activated by human proteases. Our SARS-CoV-2 JN.4 Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein of the Omicron JN.1 variant (GISAID Accession # EPI_ISL_18576661). They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus cell entry assay mediated by the SARS-CoV-2 spike protein that can be conveniently measured via luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
--	---

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/covid-19-pseudovirus/covid-19-pseudoviral-particles-jn-4-variant-coronavirus/62265>